PDF(Sci-hub)
Abstract：
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treatment of HCC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with intermediate and advanced/relapsed HCC representing the oncology societies of Taiwan (TOS), China (CSCO), India (ISMPO) Japan (JSMO), Korea (KSMO), Malaysia (MOS) and Singapore (SSO). The voting was based on scientific evidence, and was independent of the current treatment practices, the drug availability and reimbursement situations in the individual participating Asian countries.
摘要：
最新版本的欧洲医学肿瘤学会（ESMO）临床实践指南的诊断，肝细胞癌（HCC）的治疗和随访于2018年发表，并涵盖了诊断，管理,早期治疗和随访，中晚期疾病。在2018年11月的ESMO亚洲会议上，ESMO和台湾肿瘤学会（TOS）决定于2019年5月在台北举行的台湾联合癌症会议（TJCC）之后立即召开一次特别指南会议。目的是调整ESMO2018指南，以考虑与亚洲患者HCC治疗相关的实践中的种族和地理差异。这些指南代表了专家在治疗代表台湾肿瘤学会（TOS）的中晚期/复发性HCC患者方面达成的共识意见，中国（CSCO），印度(ISMPO)日本(JSMO),韩国(KSMO),马来西亚（MOS）和新加坡（SSO）。投票是基于科学证据，并且独立于当前的治疗实践，各个参与亚洲国家的药物供应和报销情况。
